2020
DOI: 10.2147/jep.s242958
|View full text |Cite
|
Sign up to set email alerts
|

<p><em>MET</em> Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?</p>

Abstract: Gastric cancer remains a disease with a dismal prognosis. Extensive efforts to find targetable disease drivers in gastric cancer were implemented to improve patient outcomes. Beyond anti-HER2 therapy, MET pathway seems to be culprit of cancer invasiveness with MET-overexpressing tumors having poorer prognosis. Tyrosine kinase inhibitors targeting the HGF/MET pathway were studied in MET-positive gastric cancer, but no substantial benefit was proven. Some patients responded in early phase trials but later develo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
28
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(29 citation statements)
references
References 96 publications
1
28
0
Order By: Relevance
“…In this regard, cancer cells which have exon 14 skipping are sensitive to a MET inhibitor [39]. In addition to alterations, overexpression and gene amplification of MET is present in a variety of tumors and have been shown to correlate with poor prognosis [40,41]. HGF/MET signaling mediates the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), PI3K/protein kinase B (AKT), focal adhesion kinase (FAK), and STAT3/5 signaling pathway (Figure 2).…”
Section: Structure and Biological Function Of Metmentioning
confidence: 99%
“…In this regard, cancer cells which have exon 14 skipping are sensitive to a MET inhibitor [39]. In addition to alterations, overexpression and gene amplification of MET is present in a variety of tumors and have been shown to correlate with poor prognosis [40,41]. HGF/MET signaling mediates the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), PI3K/protein kinase B (AKT), focal adhesion kinase (FAK), and STAT3/5 signaling pathway (Figure 2).…”
Section: Structure and Biological Function Of Metmentioning
confidence: 99%
“…An aberrant, overactivated MET pathway promotes disease progression, and serves as a common mechanism of resistance to HER -targeted therapy. Beyond anti-HER2 therapy, the MET pathway seems to be a culprit of cancer invasiveness, with MET-overexpressing tumors having poorer prognosis [ 97 ].…”
Section: Treatment-related Biomarkers—molecular Targeted Therapymentioning
confidence: 99%
“…The MET gene encodes Hepatocyte Growth Factor (HGF) receptor, which is a member of the receptor tyrosine kinase family involved in the regulation of cell growth and differentiation in health and disease. In gastric cancer, MET represents a major oncogenic driver (i.e., proto-oncogene), and activation of the pathway promotes disease progression [83] as well as resistance to HER2-targeted treatment strategies [84] and represents an adverse prognostic factor [85]. Important growth-promoting downstream pathways are activated by MET, such as the PI3K/AKT/mTOR pathway the RAS/RAF/ERK/MAPK pathway, the STAT-3 pathway and NFkB.…”
Section: Met Alterationsmentioning
confidence: 99%
“…In the VIKTORY umbrella trial, there was a promising signal (i.e., ORR 50%) for the activity of the MET inhibitor Savolitinib in gastric cancer patients, and this compound is currently under further clinical development [91]. Mostly, however, efficacy of MET targeting TKI was marginal [83].…”
Section: Met Alterationsmentioning
confidence: 99%
See 1 more Smart Citation